Clarity Pharmaceuticals Ltd Total Liabilities
Clarity Pharmaceuticals Ltd total liabilities. Based on the latest financial reports, Clarity Pharmaceuticals Ltd (CU6) has total liabilities worth AU$12.96 Million AUD (≈ $9.17 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Clarity Pharmaceuticals Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Clarity Pharmaceuticals Ltd (2018–2026)
Total liabilities of Clarity Pharmaceuticals Ltd from 2018 to 2026. This chart illustrates how Clarity Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Clarity Pharmaceuticals Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Clarity Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Clarity Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Groenlandsbanken AS
CO:GRLA
|
Denmark | Dkr9.93 Billion |
|
Hellenic Exchanges - Athens Stock Exchange SA
AT:EXAE
|
Greece | €494.17 Million |
|
Nanjing Huamai Tech Co Ltd
SHG:603042
|
China | CN¥769.61 Million |
|
Organización Cultiba S.A.B. de C.V
MX:CULTIBAB
|
Mexico | MX$443.64 Million |
|
Doright Co.Ltd.
SHE:300950
|
China | CN¥424.15 Million |
|
Protec Co. Ltd
KQ:053610
|
Korea | ₩101.04 Billion |
|
Beijing Dynamic Power Co Ltd
SHG:600405
|
China | CN¥1.33 Billion |
|
Trastor Real Estate Investment Company SA
AT:TRASTOR
|
Greece | €452.48 Million |
Liability Composition Analysis (2018–2026)
This chart breaks down Clarity Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Clarity Pharmaceuticals Ltd total assets.
Liquidity & Leverage Metrics
Clarity Pharmaceuticals Ltd Total Liabilities Ratios Explained
Clarity Pharmaceuticals Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Clarity Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Clarity Pharmaceuticals Ltd (2018–2026)
The table below shows the annual total liabilities of Clarity Pharmaceuticals Ltd from 2018 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | AU$12.96 Million ≈ $9.17 Million |
+18.41% |
| 2025-06-30 | AU$10.94 Million ≈ $7.74 Million |
+31.32% |
| 2024-06-30 | AU$8.33 Million ≈ $5.90 Million |
+7.91% |
| 2023-06-30 | AU$7.72 Million ≈ $5.46 Million |
+1.78% |
| 2022-06-30 | AU$7.59 Million ≈ $5.37 Million |
+224.81% |
| 2021-06-30 | AU$2.34 Million ≈ $1.65 Million |
+144.26% |
| 2020-06-30 | AU$956.09K ≈ $676.50K |
-15.87% |
| 2019-06-30 | AU$1.14 Million ≈ $804.07K |
+32.59% |
| 2018-06-30 | AU$857.04K ≈ $606.41K |
-- |
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic rad… Read more